Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

被引：0
|
作者：
U Platzbecker
H K Al-Ali
N Gattermann
D Haase
V Janzen
J Krauter
K Götze
R Schlenk
F Nolte
A Letsch
O G Ottmann
A Kündgen
M Lübbert
U Germing
M Wermke
H Reinhard
C Weiss
K Lieder
G Ehninger
O Leismann
A Giagounidis
机构：
[1] Universitätsklinikum Dresden,
[2] Universitätsklinikum Leipzig,undefined
[3] Universitätsklinikum Düsseldorf,undefined
[4] Universitätsmedizin Göttingen,undefined
[5] Universitätsklinikum Bonn,undefined
[6] Medizinische Hochschule Hannover,undefined
[7] Klinikum rechts der Isar der Technischen Universität München,undefined
[8] Universitätsklinikum Ulm,undefined
[9] Universitätsmedizin Mannheim,undefined
[10] Charité Berlin,undefined
[11] Universitätsklinikum Frankfurt,undefined
[12] Universitätsklinikum Freiburg,undefined
[13] Novartis Pharma GmbH Nürnberg,undefined
[14] Marienhospital Düsseldorf,undefined
来源：
Leukemia | 2014年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：696 / 698
页数：2
相关论文
共 50 条
  • [1] Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
    Platzbecker, U.
    Al-Ali, H. K.
    Gattermann, N.
    Haase, D.
    Janzen, V.
    Krauter, J.
    Goetze, K.
    Schlenk, R.
    Nolte, F.
    Letsch, A.
    Ottmann, O. G.
    Kuendgen, A.
    Luebbert, M.
    Germing, U.
    Wermke, M.
    Reinhard, H.
    Weiss, C.
    Lieder, K.
    Ehninger, G.
    Leismann, O.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (03) : 696 - 698
  • [2] SINGLE AGENT HDAC-INHIBITION WITH PANOBINOSTAT (LBH589) HAS VERY LIMITED ACTIVITY IN TRANSFUSION DEPENDENT LOW OR INT-1 MDS PATIENTS - RESULTS OF THE GEPARD TRIAL OF THE GERMAN MDS STUDY GROUP
    Platzbecker, U.
    Al-Ali, H.
    Gattermann, N.
    Haase, D.
    Janzen, V.
    Krauter, J.
    Goetze, K.
    Schlenk, R.
    Nolte, F.
    Letsch, A.
    Ottmann, O.
    Kuendgen, A.
    Luebbert, M.
    Germing, U.
    Wermke, M.
    Fritsche, P.
    May, C.
    Lieder, K.
    Ehninger, G.
    Leismann, O.
    Giagounidis, A.
    HAEMATOLOGICA, 2012, 97 : 363 - 363
  • [3] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Fukutomi, Akira
    Hatake, Kiyohiko
    Matsui, Kaoru
    Sakajiri, Sakura
    Hirashima, Tomonori
    Tanii, Hiromi
    Kobayashi, Ken
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1096 - 1106
  • [4] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Akira Fukutomi
    Kiyohiko Hatake
    Kaoru Matsui
    Sakura Sakajiri
    Tomonori Hirashima
    Hiromi Tanii
    Ken Kobayashi
    Nobuyuki Yamamoto
    Investigational New Drugs, 2012, 30 : 1096 - 1106
  • [5] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours
    Okamoto, N.
    Hatake, K.
    Yamamoto, N.
    Takahashi, S.
    Boku, N.
    Kobayashi, K.
    Sakatani, K.
    Hirashima, T.
    Matsui, K.
    EJC SUPPLEMENTS, 2008, 6 (12): : 133 - 133
  • [6] A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma.
    Wolf, Jeffrey Lee
    Siegel, David
    Matous, Jeffrey
    Lonial, Sagar
    Goldschmidt, Hartmut
    Schmitt, Stefan
    Vij, Ravi
    De Malgalhaes-Silverman, Margarida
    Abonour, Rafat
    Jalaluddin, Muhammad
    Li, Martha
    Hazell, Katharine
    Bourquelot, Priscille M.
    Mateos, Maria-Victoria
    Anderson, Kenneth C.
    Spencer, Andrew
    Harousseau, Jean-Luc
    Blade, Joan
    BLOOD, 2008, 112 (11) : 957 - 957
  • [7] Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)
    Fenaux, Pierre
    Raza, Azra
    Vellenga, Edo
    Platzbecker, Uwe
    Santini, Valeria
    Samarina, Irina
    Van Eygen, Koen
    Diez-Campelo, Maria
    Patnaik, Mrinal M.
    Sherman, Laurie
    Sun, Libo
    Varsos, Helen
    Rose, Esther
    Rizo, Aleksandra
    Steensma, David P.
    BLOOD, 2017, 130
  • [8] Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 127 - 129
  • [9] A PHASE II INTERNATIONAL, MULTICENTER STUDY OF ORAL PANOBINOSTAT (LBH589) IN PATIENTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)
    Bernengo, M. G.
    Vanaclocha, F.
    Duvic, M.
    Kuzel, T.
    Kerdel, F.
    Pinter-Brown, L.
    Bosly, A.
    Okada, C.
    Breneman, D.
    Zinzani, P. L.
    Becker, J.
    Hughey, L.
    Ardaiz, M.
    Zain, J.
    Zhang, L.
    Hirawat, S.
    Laird, G.
    Johnson, D.
    Prince, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 109 - 109
  • [10] A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Mateos, M. V.
    Spencer, A.
    Taylor, K.
    Lonial, S.
    De la Rubia, J.
    Facon, T.
    Bengoudifa, R.
    Klebsattel, M.
    Hazell, K.
    Bourquelot, P.
    Rossi, J. F.
    Harousseau, J. L.
    Jagannath, S.
    Wolf, J.
    San Miguel, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 158 - 158
12345